دورية أكاديمية
أعرض في EDS

Hip Involvement in Juvenile Idiopathic Arthritis: A Roadmap From Arthritis to Total Hip Arthroplasty or How Can We Prevent Hip Damage?

التفاصيل البيبلوغرافية
العنوان: Hip Involvement in Juvenile Idiopathic Arthritis: A Roadmap From Arthritis to Total Hip Arthroplasty or How Can We Prevent Hip Damage?
المؤلفون: Sorokina LS; Department of Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia., Avrusin IS; Department of Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia., Raupov RK; Department of Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.; Leningrad Regional Children's Hospital, Saint Petersburg, Russia.; Saint Petersburg State Health Care Establishment the City Hospital, Saint Petersburg, Russia., Lubimova NA; Almazov National Research Medical Centre, Saint Petersburg, Russia., Khrypov SV; St. Petersburg Clinical Scientific and Practical Center of Specialized Types of Medical Aid (Oncological), Saint Petersburg, Russia., Kostik MM; Department of Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.; Almazov National Research Medical Centre, Saint Petersburg, Russia.
المصدر: Frontiers in pediatrics [Front Pediatr] 2021 Nov 05; Vol. 9, pp. 747779. Date of Electronic Publication: 2021 Nov 05 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101615492 Publication Model: eCollection Cited Medium: Print ISSN: 2296-2360 (Print) Linking ISSN: 22962360 NLM ISO Abbreviation: Front Pediatr Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media SA, [2013]-
مستخلص: Objectives: To describe the clinical characteristics of hip involvement in juvenile idiopathic arthritis (JIA) from arthritis to hip osteoarthritis (HOA) and total hip arthroplasty (THA). Study Design: Seven hundred fifty-three patients aged 2-17 years with JIA were included in the study. The comparison analysis was performed between the following subgroups: (i) JIA without hip involvement ( n = 600; 79.7%) vs. JIA with hip involvement without HOA ( n = 105; 13.9%), (ii) JIA with hip involvement with HOA, but without THA ( n = 32; 4.3%) and JIA with hip involvement with HOA and with THA ( n = 16; 2.1%). Clinical, laboratory characteristics and treatment regimens compared. Results: Hip involvement was present in 20.3% of patients. HOA was present in 6.4% (12 * 1,000 patient-years) of the entire JIA group and 31.4% of patients with hip involvement. Sixteen patients (2.1%; 4.0 * 1,000 patient-years) required THA. The following factors were associated with HOA: sJIA (OR = 3.6, p = 0.008; HR = 3.0, p = 0.002), delayed remission (OR = 4.2, p = 0.004; HR = 1.4, p = 0.538), delay in biologic therapy initiation (OR = 7.5, p = 0.00001; HR = 6.7, p = 0.002), alkaline phosphatase <165 U\l (OR = 4.1, p = 0.0003; HR = 5.2, p = 0.000004), treatment with corticosteroids (CS) (OR = 2.6, p = 0.008; HR = 1.2, p = 0.670), cumulative corticosteroids >2,700 mg (OR = 4.3, p = 0.032; HR = 1.4, p = 0.527). The following factors were associated with THA: delay in biologic treatment initiation (OR = 1.04, p = 0.0001; HR = 9.1, p = 0.034), delayed hip involvement (OR = 5.2, p = 0.002; HR = 3.0, p = 0.044), and methylprednisolone pulse therapy (OR = 10.8, p = 0.0000001; HR = 5.6, p = 0.002). Conclusion: Both sJIA and systemic CS, impaired calcium-phosphorus metabolism, and delayed hip arthritis are associated with HOA development in JIA. HOA is considered to be a severe adverse event of CS treatment, especially delayed hip involvement.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Sorokina, Avrusin, Raupov, Lubimova, Khrypov and Kostik.)
References: J Rheumatol. 2004 Feb;31(2):390-2. (PMID: 14760812)
Orthopedics. 2014 Jul;37(7):e631-6. (PMID: 24992058)
J Arthroplasty. 2015 Sep;30(9):1506-1512.e5. (PMID: 25900167)
BMJ Open. 2017 Jul 21;7(7):e016788. (PMID: 28733303)
Clin Orthop Relat Res. 2014 Feb;472(2):637-44. (PMID: 24136805)
Rev Rhum Ed Fr. 1994 Oct;61(9):583-9. (PMID: 7858591)
J Clin Orthop Trauma. 2018 Apr-Jun;9(2):103-106. (PMID: 29896009)
Clin Exp Rheumatol. 2017 Jul-Aug;35(4):700-710. (PMID: 28240590)
J Rheumatol. 2003 Mar;30(3):585-93. (PMID: 12610821)
Arthritis Rheumatol. 2014 Jun;66(6):1432-9. (PMID: 24591462)
Rev Esp Cir Ortop Traumatol. 2017 Sep - Oct;61(5):331-338. (PMID: 28728961)
Curr Opin Rheumatol. 2002 Sep;14(5):536-41. (PMID: 12192251)
Cureus. 2019 Jul 13;11(7):e5131. (PMID: 31341750)
J Bone Joint Surg Br. 2011 Apr;93(4):443-8. (PMID: 21464480)
J Arthroplasty. 2018 Dec;33(12):3704-3711. (PMID: 30217401)
Arthritis Rheum. 2006 May;54(5):1595-601. (PMID: 16645998)
Lancet. 2007 Mar 3;369(9563):767-778. (PMID: 17336654)
Orthop Rev (Pavia). 2018 Jul 04;10(2):7542. (PMID: 30057722)
J Arthroplasty. 1998 Apr;13(3):259-65. (PMID: 9590636)
Exp Ther Med. 2019 Dec;18(6):4653-4660. (PMID: 31772640)
Int J Rheum Dis. 2019 Sep;22(9):1661-1669. (PMID: 31273940)
PLoS Med. 2019 Feb 26;16(2):e1002750. (PMID: 30807586)
Rheumatol Int. 2019 Jan;39(1):13-27. (PMID: 30276425)
J Rheumatol. 2014 Jun;41(6):1171-7. (PMID: 24786929)
J Pediatr Orthop. 1992 Jan;12(1):45-53. (PMID: 1732294)
Arthritis Rheum. 2000 Nov;43(11):2402-9. (PMID: 11083261)
Clin Rheumatol. 2008 Jun;27(6):791-4. (PMID: 18274812)
فهرسة مساهمة: Keywords: avascular osteonecrosis of the femoral head; corticosteroids; hip osteoarthritis; juvenile idiopathic arthritis; total hip arthroplasty
تواريخ الأحداث: Date Created: 20211122 Latest Revision: 20211123
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8604160
DOI: 10.3389/fped.2021.747779
PMID: 34805045
قاعدة البيانات: MEDLINE
الوصف
تدمد:2296-2360
DOI:10.3389/fped.2021.747779